News
BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021
Bergen, Norway, 16 November 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL data on BEMCENTINIB IN STK11-POSITIVE NSCLC at SITC Annual Meeting 2021
Bergen, Norway, 9 November 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB in STK11-mutated advanced/metastatic Non-small cell lung cancer (NSCLC)
Bergen, Norway, 9 November 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read More
BERGENBIO ASA: LEADERSHIP CHANGE
Bergen, Norway, 22 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL…
Read MoreBERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML PATIENTS AT EHA VIRTUAL MEETING
Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML…
Read MoreBERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
Bergen, Norway, 10 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stagebiopharmaceutical company developing novel,…
Read More
